Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrence 2Neoplasms 2Uterine Cervical Neoplasms 1Pregnancy Related 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Endometrial Neoplasms 1Burkitt Lymphoma 1

Interventions

Cisplatin 22pembrolizumab 21Carboplatin 12Radiotherapy 11Paclitaxel 11Brachytherapy 11Drug Therapy 10Bevacizumab 9Blood Specimen Collection 7Colposcopy 6Specimen Handling 5Injections 5toripalimab 4Taxes 4Surveys and Questionnaires 4Nivolumab 4Mass Screening 4Human Papillomavirus DNA Tests 4Gemcitabine 4Chemotherapy, Adjuvant 4Chemoradiotherapy 4spartalizumab 3lenvatinib 3camrelizumab 3aldesleukin 3Restraint, Physical 3Radiation 3Fulvestrant 3Cyclophosphamide 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Uterine Cervical Neoplasms × Antibodies, Monoclonal × Clear all
NCT06455072 2024-06-12

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Fujian Cancer Hospital

Phase 2 Recruiting
37 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡